Ketamine for the treatment of major depression: a systematic review and meta-analysis (Nikolin, et al, 2023)

Our findings suggested that effect sizes for depression severity, as well as response and remission rates, were numerically greater for (generic) racemic ketamine than esketamine (sold as Spravato). Higher doses were more effective than low doses. Differences were evident in initial effects, ongoing treatment, and lasting effects after the final dose.